The National Healthcare Security Administration announced the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2023) recently. Xingqi Zirun® Cyclosporine Eye Drops (Ⅱ) as a NRDL-negotiated drug was renewed successfully and included in the 2023 National Reimbursement Drug List (NRDL). The scope of medical insurance payment was adjusted from "a medication that is used to promote tear secretion in patients with dry eye syndrome and is applicable to reduced tear production caused by ocular inflammation associated with keratoconjunctivitis sicca" to "dry eye syndrome".